Brand Insights - Thought Leadership | Paid Program
Brand Insights - Thought Leadership | Paid Program | BioPharm Communications
Brand Insights - Thought Leadership | Paid Program
Brand Insights - Thought Leadership | Paid Program
Brand Insights - Thought Leadership | Paid Program
Brand Insights - Thought Leadership | Paid Program
Brand Insights - Thought Leadership | Paid Program
How non-endemic platforms can help brand teams amplify their use of KOLs in HCP outreach
Brand Insights - Thought Leadership | Paid Program
Marketers are working to reimagine how they leverage key opinion leader (KOL) support during COVID-19.
Brand Insights - Thought Leadership | Paid Program
Non-personal promotion is a foundational component of most brands’ omnichannel marketing strategy.
Brand Insights - Thought Leadership from Marketers I Paid Program
The current COVID-19 pandemic has taken the world of HCP marketing and turned it upside down. Biopharma has had to make instantaneous decisions on how to market in this new environment, who to market to, which tactics to significantly increase, and which tactics to walk away from-all with no historical playbook.
Brand Insights - Thought Leadership from Marketers I Paid Program
The impact of vacant sales territories on overall brand performance is often underestimated within pharma and biotech companies.
Brand Insights - Thought Leadership from Marketers I Paid Program
Pharma and biotech marketers are facing more challenges than ever in communicating brand messages to target healthcare professionals (HCPs).
Advertisement
Advertisement
Trending on PharmExec
1
Pharma M&A Roundup: Novartis to Acquire Pan-Mutant-Selective PI3Kα Inhibitor from Synnovation Therapeutics, Collegium to Acquire Azstarys from Corium Therapeutics
2
Pharmaceutical Executive Daily: FDA Approves Wegovy HD
3
FDA Approves Wegovy HD Injectable Under Accelerated Approval
4
What Are the ‘Last Mile Issues’ Impacting Pharma?
5